Observational studyPloS one2026
The role of quantitative T1 and T2 mapping for detecting minimal hepatic encephalopathy in chronic hepatic schistosomiasis patients.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimal hepatic encephalopathy (MHE) is a frequent neurocognitive complication in chronic hepatic schistosomiasis (CHS) patients. Conventional diagnostic tools are time-consuming and influenced by education level. Quantitative MRI mapping offers a potential non-invasive biomarker for MHE, but its role in CHS remains unclear.
aimThis study aimed to evaluate the diagnostic value of quantitative T1 and T2 mapping for detecting MHE in CHS patients.
methodsThis prospective cross-sectional observational study was conducted from August 2023 to July 2024. A total of 88 CHS patients were enrolled and divided into MHE (n = 50) and non-MHE group (n = 38). MHE was assessed using the number connection test-A (NCT-A) and digit symbol test (DST). All participants underwent 3.0T MRI with T1 and T2 mapping. Group comparisons, correlation analyses, logistic regression, and receiver operating characteristic (ROC) curve analyses were performed.
resultsMHE patients exhibited significantly lower T1 values across multiple brain regions, particularly the globus pallidus (all p < 0.001). T2 values showed no significant differences between groups. Multivariable regression confirmed that lower T1 values were independently associated with MHE (p = 0.009). ROC analysis demonstrated excellent diagnostic performance of globus pallidus T1 values (AUC = 0.92, 95% CI: 0.86-0.99), with sensitivity of 0.97 and specificity of 0.90. T1 values were also correlated with neuropsychological tests (NCT-A: r = -0.345, p < 0.001; DST: r = 0.232, p = 0.029). However, T2 values showed no significant group differences or diagnostic value.
conclusionQuantitative T1 mapping, rather than T2 mapping, could be used as a potential non-invasive biomarker for detecting MHE in CHS patients. This approach offers an objective complement to psychometric testing and may facilitate earlier diagnosis and monitoring of MHE progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.